Press Releases

 
Press Releases
Date Title and Summary View
5/21/14 VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox's Chief Executive Officer, will present at two upcoming investor...
5/14/14 VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its l...
5/13/14 VANCOUVER, British Columbia, May 13, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today provided a corporate update and reported financial results for the first quarter ending March 31, 2...
3/12/14 VANCOUVER, British Columbia, March 12, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters' option to purchase ad...
3/7/14 VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses. ...
12/17/13 Vancouver, British Columbia – December 17, 2013 - Aquinox Pharmaceuticals Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of its lead clinical candidate, AQX-1125, a SHIP1 activator, for the treatment of exacerb...
7/23/13 Vancouver, British Columbia – July 23, 2013 - Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has begun dosing patients in a Phase II clinical tr...
4/3/13 Vancouver, British Columbia - April 3, 2013 Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has secured U.S. $18 million in the close of a Series C financing led by Johnson &a...
11/10/11 Vancouver, British Columbia - November 10, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has initiated two Phase IIa clinical studies. Both studies will measure AQX...
1/5/11 Vancouver, British Columbia - January 5, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has initiated a Phase I clinical trial of its lead compound, AQX-1125....
Page: FirstPrevious ...
8
NextLast
= add release to Briefcase